Special Issue "Molecular Mechanisms Underlying Cystic Diseases of the Kidney and Novel Therapies"

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Nephrology".

Deadline for manuscript submissions: 30 June 2023 | Viewed by 142

Special Issue Editors

Dr. Andreea Gabriella Andronesi
E-Mail Website
Guest Editor
Nephrology Department, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
Interests: genetic kidney diseases; onco-nephrology; tuberous sclerosis complex
Dr. Bogdan Sorohan
E-Mail Website
Guest Editor
Kidney Transplant Department, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
Interests: kidney transplant; autosomal dominant polycystic kidney disease
Dr. Gener Ismail
E-Mail Website
Guest Editor
Nephrology Department, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
Interests: autoimmune diseases involving kidneys; genetic diseases of the kidneys; nephropathology

Special Issue Information

Dear Colleagues, 

Autosomal dominant polycystic kidney disease (PKD) is the most common hereditary kidney disease worldwide, and is one of the most important causes of end-stage kidney disease requiring kidney replacement therapy. It is characterized by multiple, bilateral renal cysts leading to an increased kidney volume and progressive loss of kidney function. It is a systemic disorder that also affects the liver, pancreas, spleen, seminal vesicles, arachnoid membrane, and endothelium. Currently, there is no approved treatment for autosomal recessive polycystic kidney disease, and tolvaptan is the only approved drug that alleviates the symptoms of ADPKD. However, tolvaptan has only a modest effect on disease progression, and its long-term use is associated with many side effects. Therefore, there is still a pressing need to better understand the fundamental mechanisms behind PKD development.

The aim of this Special Issue is to bring together international experts to provide a comprehensive overview of this important and dynamic research field. Therefore, we invite you to participate by contributing either an original article or a review focused on some aspects of this complex topic. We invite colleagues from all over the world to report their clinical experience and fundamental science about present aspects and future perspectives regarding polycystic kidney diseases, including their genetics and metabolic pathways, systemic responses that affect their development and progression, as well as information regarding epigenetic factors involved in their development and progression. We also welcome reviews, clinical and fundamental science studies regarding therapeutic options in ADPKD, ARPKD, as well as acquired cystic disease of the kidney, complex cysts of the kidney, starting from the pathophysiology of these diseases.

Dr. Andreea Gabriella Andronesi
Dr. Bogdan Sorohan
Dr. Gener Ismail
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • polycystic kidney disease
  • tolvaptan
  • polycystin

Published Papers

This special issue is now open for submission.
Back to TopTop